The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods

摘要

Alzheimer’s disease (AD) and vascular dementia (VaD) are twoof the most common forms of dementia, resulting in increaseddisability and mortality, impaired quality of life, and seriousburdens on society and caregivers. However, the presentlyavailable drugs can only alleviate symptoms for a short timewithout delaying the progression of the cognitive disorders. Since2003, no new drugs have been approved by the US Food andDrug Administration for the treatment of AD. In 2019, phase IIIclinical trials of crenezumab and aducanumab, two anti-amyloidbeta monoclonal antibodies, were terminated. The scant progressin clinical trials urges efforts towards an alternative therapeuticstrategy for dementia.